

## Neonatal BCG Assessment

Mother's Details		Baby's Details	
Name:		Name:	
Address:		Address:	
NHI:	NHI:	D.O.B:	
Home Phone:			
Mobile Phone:			
Email Address:			

All newborns must be assessed for eligibility.

All eligible babies must be offered neonatal BCG vaccine

<p><b>ELIGIBILITY SCREEN (by LMC)</b></p> <p>If the answer is <b>yes</b> to any of the below questions then the baby is at risk of exposure to TB. Neonatal <b>BCG is recommended</b> for this baby <b>unless there are contraindications*</b> to BCG vaccination.</p>	<p>✓ = YES</p> <p>✗ = NO</p>	
<p>A. Will the baby be living in a house or family/whanau with a person who currently has TB or has a past history of TB?</p>		
<p>B. Does the baby have one or both parents or household members who, within the last five years, lived for a period of six months or more in countries with high numbers of TB? <i>PTO for country details</i></p> <p><b>If yes, list country/countries:</b> _____</p>		
<p>C. Will the baby, during the first five years of life, be living for three months or longer in a country with high numbers of TB and is likely to be exposed to those with TB? <i>PTO for country details</i></p> <p><b>If yes, list country/countries:</b> _____</p>		
<p><b>Staff Name:</b> _____</p>	<p><b>Staff Signature:</b> _____</p>	<p><b>Date:</b> _____</p>

\* Contraindications include malignant conditions, immune compromising conditions (including maternal HIV – BCG is contraindicated until baby shown to be HIV negative at 12-15 months of age), immunosuppressive treatments (in baby, or in mother during pregnancy e.g. biologic agents such as TNF alpha blockers – BCG contraindicated until baby is 8-9 months old), baby exposed to infectious TB case (BCG contraindicated until baby has been investigated for TB infection).

Email completed form to ARPHS: [bcg@adhb.govt.nz](mailto:bcg@adhb.govt.nz)

Attention BGC Programme

Contact 0800 367 224

Countries with TB incidence of  $\geq 40$  per 100,000 population

Afghanistan	Ghana	Pakistan
Algeria	Greenland	Palau
Angola	Guam	Panama
Azerbaijan	Guinea	Papua New Guinea
Bangladesh	Guinea-Bissau	Paraguay
Benin	Guyana	Peru
Bhutan	Haiti	Philippines
Bolivia (Plurinational State of)	India	Republic of Korea
Botswana	Indonesia	Republic of Moldova
Brazil	Iraq	Romania
Brunei Darussalam	Kazakhstan	Russian Federation
Burkina Faso	Kenya	Rwanda
Burundi	Kiribati	São Tomé and Príncipe
Cabo Verde	Kyrgyzstan	Senegal
Cambodia	Lao People's Democratic Republic	Sierra Leone
Cameroon	Lesotho	Singapore
Central African Republic	Liberia	Solomon Islands
Chad	Libya	Somalia
China	Lithuania	South Africa
China, Hong Kong SAR	Madagascar	South Sudan
China, Macao SAR	Malawi	Sri Lanka
Congo	Malaysia	Sudan
Côte d'Ivoire	Mali	Tajikistan
Democratic People's Republic of Korea	Marshall Islands	Thailand
Democratic Republic of the Congo	Mauritania	Timor-Leste
Djibouti	Micronesia (Federated States of)	Turkmenistan
Dominican Republic	Mongolia	Tuvalu
Ecuador	Morocco	Uganda
El Salvador	Mozambique	Ukraine
Equatorial Guinea	Myanmar	United Republic of Tanzania
Eritrea	Namibia	Uzbekistan
Eswatini	Nauru	Vanuatu
Ethiopia	Nepal	Venezuela (Bolivarian Republic of)
Fiji	Nicaragua	Viet Nam
Gabon	Niger	Yemen
Gambia	Nigeria	Zambia
Georgia	Niue	Zimbabwe
	Northern Mariana Islands	

Source: Immunisation handbook 2017. Appendix 8.

[https://www.health.govt.nz/system/files/documents/publications/immunisation-handbook-2017-2nd-edition-mar2018-v8.html#\\_Toc21503269](https://www.health.govt.nz/system/files/documents/publications/immunisation-handbook-2017-2nd-edition-mar2018-v8.html#_Toc21503269)

Last updated 06/04/2021